Award Year / Program / Phase:2009 / SBIR / Phase I
Agency:HHS
Principal Investigator:Richard Maki
Award Amount:$274,434.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of the proposed research is to develop an orally active inhibitor of MPO as a treatment for acute and chronic diseases. MPO is an abundant enzyme in leukocytes and its expression can be induced in
macrophages at inflammatory sites such as… More
Award Year / Program / Phase:2012 / SBIR / Phase I
Agency:HHS
Principal Investigator:Richard Maki – 858-481-8547
Award Amount:$521,453.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of the proposed research is to develop orally active inhibitors of myeloperoxidase MPO as a treatment forAlzheimer's disease. MPO is an abundant enzyme in leukocytes but its expression can be induced inastrocytes in Alzheimer's disease.… More